European Regulator Recommends Approving Moderna’s COVID-Flu Vaccine

The vaccine ‘triggered the production of adequate amounts of antibodies against both viruses,’ the agency said.

Moderna's headquarters in Cambridge, Mass., on May 8, 2020. Maddie Meyer/Getty Images

Europe’s medical regulator on Feb. 27 recommended approval of Moderna’s COVID-19-influenza vaccine.

Data show the vaccine, known as mCombriax, “triggered the production of adequate amounts of antibodies against both viruses,” the European Medicines Agency said in a statement.